Cancer Deals That Grabbed Headlines In 2020
Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 24 deals with upfront value of at least $100m.
You may also be interested in...
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
Very early launch numbers look good in France and Germany, but US launch will be more challenging due to a fragmented patient base, the company said. Launch price is a flat $899 per vial.